10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $71,344.80 in Stock

10x Genomics, Inc. (NASDAQ:TXG) CFO Justin J. Mcanear sold 2,936 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $71,344.80. Following the sale, the chief financial officer now owns 146,203 shares of the company’s stock, valued at approximately $3,552,732.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

10x Genomics Stock Down 1.6 %

NASDAQ:TXG opened at $22.59 on Friday. 10x Genomics, Inc. has a 12 month low of $22.50 and a 12 month high of $63.57. The firm’s 50 day moving average is $30.74 and its 200 day moving average is $40.78.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, April 30th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The firm had revenue of $141.01 million for the quarter, compared to analyst estimates of $142.24 million. During the same period in the previous year, the company posted ($0.44) earnings per share. The business’s revenue was up 5.0% on a year-over-year basis. As a group, equities research analysts anticipate that 10x Genomics, Inc. will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On 10x Genomics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SVB Wealth LLC boosted its position in 10x Genomics by 92.1% during the fourth quarter. SVB Wealth LLC now owns 1,446,552 shares of the company’s stock worth $80,949,000 after purchasing an additional 693,422 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of 10x Genomics by 32.9% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock valued at $127,786,000 after buying an additional 565,059 shares in the last quarter. Bleakley Financial Group LLC bought a new position in 10x Genomics in the 4th quarter worth approximately $234,000. ARK Investment Management LLC boosted its holdings in 10x Genomics by 35.0% in the 4th quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock worth $226,150,000 after buying an additional 1,047,827 shares during the period. Finally, Vanguard Group Inc. grew its stake in 10x Genomics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company’s stock valued at $367,270,000 after buying an additional 354,921 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TXG. Barclays reduced their target price on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. Canaccord Genuity Group dropped their target price on shares of 10x Genomics from $65.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, April 29th. Stifel Nicolaus reduced their target price on 10x Genomics from $63.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Finally, TD Cowen downgraded 10x Genomics from a “buy” rating to a “hold” rating and decreased their price target for the company from $57.00 to $32.00 in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, 10x Genomics has an average rating of “Moderate Buy” and a consensus target price of $48.50.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.